Predictive algorithms for adjuvant therapy: TransATAC
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trialThe Lancet Oncology, 2010
- Effect of Body Mass Index on Recurrences in Tamoxifen and Anastrozole Treated Women: An Exploratory Analysis From the ATAC TrialJournal of Clinical Oncology, 2010
- Ki67 in breast cancer: prognostic and predictive potentialThe Lancet Oncology, 2010
- Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus TamoxifenJournal of Clinical Oncology, 2010
- Pharmacogenomic Variation of CYP2D6 and the Choice of Optimal Adjuvant Endocrine Therapy for Postmenopausal Breast Cancer: A Modeling AnalysisJNCI: Journal of the National Cancer Institute, 2008
- Relationship Between Quantitative Estrogen and Progesterone Receptor Expression and Human Epidermal Growth Factor Receptor 2 (HER-2) Status With Recurrence in the Arimidex, Tamoxifen, Alone or in Combination TrialJournal of Clinical Oncology, 2008
- Pharmacogenetics of Tamoxifen Biotransformation Is Associated With Clinical Outcomes of Efficacy and Hot FlashesJournal of Clinical Oncology, 2005
- Retrospective Analysis of Time to Recurrence in the ATAC Trial According to Hormone Receptor Status: An Hypothesis-Generating StudyJournal of Clinical Oncology, 2005
- Proliferation Marker Ki-67 in Early Breast CancerJournal of Clinical Oncology, 2005
- Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trialThe Lancet, 2002